Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.35 |
| ▸ | PGD | P52209 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.32 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2469230 | 0.83 | GPR84 (0.37) | LMNASLC22A6SMN1; SMN2GPR84PGD | |
| SCHEMBL11852711 | 0.81 | LMNA (0.39) | LMNASLC22A6SMN1; SMN2CACNA2D1CACNB3 | |
| SCHEMBL15987193 | 0.77 | SLC22A6 (0.42) | LMNASLC22A6SMN1; SMN2GPR84PGD | |
| SCHEMBL886928 | 0.77 | SLC22A6 (0.42) | LMNASLC22A6SMN1; SMN2GPR84PGD | |
| SCHEMBL22906066 | 0.75 | — | — | |
| SCHEMBL156206 | 0.75 | — | — | |
| SCHEMBL4598341 | 0.74 | ALOX15 (0.47) | LMNASLC22A6SMN1; SMN2MAPTGABRR1 | |
| SCHEMBL9730228 | 0.74 | — | — | |
| SCHEMBL3363687 | 0.73 | LMNA (0.57) | LMNA | |
| Bromoacetic Acid SCHEMBL1982827 | 0.73 | LMNA (0.57) | LMNASLC22A6CACNA2D1CACNB3CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10551566-B2 | Method of preparing an optical connector and optical devices comprising the optical connector prepared thereby | DOW SILICONES CORPORATION (US) | 2020-02-04 | — | — | US | disclosed |
| US-10435585-B2 | Curable composition, method of preparing cured article, and cured article formed thereby | DOW CORNING CORPORATION (US) | 2019-10-08 | — | — | US | disclosed |
| EP-2996867-B1 | METHOD OF PREPARING AN ARTICLE AND ARTICLE PREPARED THEREBY | DOW SILICONES CORP (US) | 2018-09-19 | — | — | EP | disclosed |
| EP-3164449-A1 | METHODS FOR PREPARING ARTICLES AND ASSOCIATED ARTICLES PREPARED THEREBY | Dow Corning Corporation (US) | 2017-05-10 | — | — | EP | disclosed |
| US-20170107331-A1 | Methods For Preparing Articles And Associated Articles Prepared Thereby | DOW CORNING CORPORATION (US) | 2017-04-20 | — | — | US | disclosed |
| US-20160349455-A1 | METHOD OF PREPARING AN OPTICAL CONNECTOR AND OPTICAL DEVICES COMPRISING THE OPTICAL CONNECTOR PREPARED THEREBY | DOW SILICONES CORPORATION | 2016-12-01 | — | — | US | disclosed |
| US-20160102226-A1 | Curable Composition, Method Of Preparing Cured Article, And Cured Article Formed Thereby | DOW SILICONES CORPORATION | 2016-04-14 | — | — | US | disclosed |
| EP-2996867-A1 | METHOD OF PREPARING AN ARTICLE AND ARTICLE PREPARED THEREBY | Dow Corning Corporation (US) | 2016-03-23 | — | — | EP | disclosed |
| EP-2997101-A1 | CURABLE COMPOSITION, METHOD OF PREPARING CURED ARTICLE, AND CURED ARTICLE FORMED THEREBY | Dow Corning Corporation (US) | 2016-03-23 | — | — | EP | disclosed |
| US-20160077279-A1 | Method of Preparing an Article and Article Prepared Thereby | DOW SILICONES CORPORATION | 2016-03-17 | — | — | US | disclosed |
| WO-2016003636-A1 | METHODS FOR PREPARING ARTICLES AND ASSOCIATED ARTICLES PREPARED THEREBY | DOW CORNING CORPORATION (US) | 2016-01-07 | — | — | WO | disclosed |
| WO-2014186514-A1 | CURABLE COMPOSITION, METHOD OF PREPARING CURED ARTICLE, AND CURED ARTICLE FORMED THEREBY | DOW CORNING CORPORATION (US) | 2014-11-20 | — | — | WO | disclosed |
| WO-2014186549-A1 | METHOD OF PREPARING AN ARTICLE AND ARTICLE PREPARED THEREBY | DOW CORNING CORPORATION (US) | 2014-11-20 | — | — | WO | disclosed |
| EP-1692209-B1 | ACTIVE ENERGY RAY-CURABLE ORGANOPOLYSILOXANE RESIN COMPOSITION, LIGHT-TRANSMITTING COMPONENT, AND METHOD FOR MANUFACTURING THE LIGHT-TRANSMITTING COMPONENT | DOW CORNING TORAY CO LTD (JP) | 2013-10-02 | — | — | EP | disclosed |
| US-7771794-B2 | Active energy ray-curable, organopolysiloxane resin composition, light-transmitting component, and method for manufacturing the light-transmitting component | DOW CORNING CORPORATION (US) | 2010-08-10 | — | — | US | disclosed |
| US-20080058441-A1 | Active Energy Ray-Curable, Organopolysiloxane Resin Composition, Light-Transmitting Component, And Method For Manufacturing The Light-Transmitting Component | DOW TORAY CO., LTD. (JP) | 2008-03-06 | — | — | US | disclosed |
| EP-1692209-A1 | ACTIVE ENERGY RAY-CURABLE ORGANOPOLYSILOXANE RESIN COMPOSITION, LIGHT-TRANSMITTING COMPONENT, AND METHOD FOR MANUFACTURING THE LIGHT-TRANSMITTING COMPONENT | Dow Corning Toray Co., Ltd. (JP) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005056640-A1 | ACTIVE ENERGY RAY-CURABLE ORGANOPOLYSILOXANE RESIN COMPOSITION, LIGHT-TRANSMITTING COMPONENT, AND METHOD FOR MANUFACTURING THE LIGHT-TRANSMITTING COMPONENT | DOW CORNING TORAY CO., LTD. (JP) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435585-B2 | Curable composition, method of preparing cured article, and cured article formed thereby | SETDB1, SETD2, SETD1A | LMNA 632/4885SLC22A6 2171/4885SMN1; SMN2 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.